JP5980790B2 - バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン - Google Patents

バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン Download PDF

Info

Publication number
JP5980790B2
JP5980790B2 JP2013537895A JP2013537895A JP5980790B2 JP 5980790 B2 JP5980790 B2 JP 5980790B2 JP 2013537895 A JP2013537895 A JP 2013537895A JP 2013537895 A JP2013537895 A JP 2013537895A JP 5980790 B2 JP5980790 B2 JP 5980790B2
Authority
JP
Japan
Prior art keywords
synuclein
disease
pharmaceutical composition
ice
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013537895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543129A (ja
Inventor
ダグマー リンジ
ダグマー リンジ
グレゴリー エイ． ぺトスコ
グレゴリー エイ． ぺトスコ
クウェン ホァン
クウェン ホァン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brandeis University
Original Assignee
Brandeis University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brandeis University filed Critical Brandeis University
Publication of JP2013543129A publication Critical patent/JP2013543129A/ja
Application granted granted Critical
Publication of JP5980790B2 publication Critical patent/JP5980790B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
JP2013537895A 2010-11-05 2011-11-04 バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン Expired - Fee Related JP5980790B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41085210P 2010-11-05 2010-11-05
US41085610P 2010-11-05 2010-11-05
US61/410,856 2010-11-05
US61/410,852 2010-11-05
PCT/US2011/059465 WO2012061786A1 (en) 2010-11-05 2011-11-04 Ice cleaved alpha-synuclein a biomarker

Publications (2)

Publication Number Publication Date
JP2013543129A JP2013543129A (ja) 2013-11-28
JP5980790B2 true JP5980790B2 (ja) 2016-08-31

Family

ID=46024857

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013537895A Expired - Fee Related JP5980790B2 (ja) 2010-11-05 2011-11-04 バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン
JP2013537894A Expired - Fee Related JP6006908B2 (ja) 2010-11-05 2011-11-04 Ｉｃｅ阻害化合物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013537894A Expired - Fee Related JP6006908B2 (ja) 2010-11-05 2011-11-04 Ｉｃｅ阻害化合物およびその使用

Country Status (4)

Country Link
US (3) US9116157B2 (https=)
EP (2) EP2635907A4 (https=)
JP (2) JP5980790B2 (https=)
WO (2) WO2012061785A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9116157B2 (en) * 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
ES2950100T3 (es) 2016-12-23 2023-10-05 Casp Aid Inc Inhibición de la caspasa-1 y usos de esta para la prevención y el tratamiento de afecciones neurológicas
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
WO2019161302A1 (en) * 2018-02-16 2019-08-22 University Of Southern California Biomarkers for parkinson's disease
SG11202011296VA (en) 2018-05-15 2020-12-30 Voyager Therapeutics Inc Compositions and methods for the treatment of parkinson's disease

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
WO1991015577A1 (en) 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE
DE69226820T2 (de) 1991-06-21 1999-05-12 Merck & Co., Inc., Rahway, N.J. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
AU657701B2 (en) 1991-08-30 1995-03-23 Vertex Pharmaceuticals Incorporated Interleukin 1beta protease and interleukin 1beta protease inhibitors
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
WO1993012076A1 (en) 1991-12-13 1993-06-24 Corvas International Inc. Reagents for automated synthesis of peptide analogs
AU3479593A (en) 1992-01-31 1993-09-01 Merck & Co., Inc. Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
EP0627926B1 (en) 1992-02-21 1998-08-05 Merck & Co., Inc. (a New Jersey corp.) PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME
FR2698984B1 (fr) 1992-12-04 1995-01-06 Commissariat Energie Atomique Procédé et dispositif d'acquisition d'une image à trois dimensions d'un petit objet par palpage lumineux et moyen d'étalonnage pour la mise en Óoeuvre d'une telle acquisition.
CN1118458C (zh) 1994-03-31 2003-08-20 弗特克斯药品有限公司 作为白细胞介素抑制剂的嘧啶基衍生物
US5552400A (en) 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
EP0820464A2 (en) 1995-03-31 1998-01-28 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5798442A (en) 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
AU3359697A (en) 1996-07-08 1998-02-02 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
US6531467B2 (en) 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6610683B2 (en) 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
EP0929311B8 (en) 1996-09-12 2006-02-01 Idun Pharmaceuticals, Inc. INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS
US5968927A (en) 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
CA2268103A1 (en) 1996-10-11 1998-04-23 Warner-Lambert Company Sulfonamide substituted aspartic acid interleukin-1.beta. converting enzyme inhibitors
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
NZ334906A (en) 1996-10-11 2000-09-29 Basf Ag A sulphonamido pentanoic acid derivative useful as an interleukin-1-beta converting enzyme inhibitor
WO1998016502A1 (en) 1996-10-11 1998-04-23 Warner-Lambert Company ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
JP2002509153A (ja) 1998-01-20 2002-03-26 ワーナー−ランバート・カンパニー インターロイキン−１β変換酵素（ＩＣＥ）のインビボ阻害剤としてのＮ−［２−（５−ベンジルオキシカルボニル−アミノ−６−オキソ−２−（４−フルオロフェニル）−１，６−ジヒドロ−１−ピリミジニル）アセトキシル］−Ｌ−アスパラギン酸アルデヒド
CN1297354A (zh) 1998-03-16 2001-05-30 西托维亚公司 二肽卡斯帕酶抑制剂及其用途
DK1064298T3 (da) 1998-03-19 2009-01-19 Vertex Pharma Inhibitorer af caspaser
ES2242394T3 (es) 1998-05-05 2005-11-01 Warner-Lambert Company Llc Inhibidores de tipo succinamida de la enzima convertidora de la interleuquina 1 beta.
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US6391575B1 (en) * 1999-03-05 2002-05-21 Idun Pharmaceuticals, Inc. Methods for detecting membrane derived caspase activity and modulators thereof
JP2002539183A (ja) 1999-03-16 2002-11-19 サイトビア インコーポレイテッド 置換２−アミノベンズアミドカスパーゼインヒビターおよびその使用
CA2367862A1 (en) 1999-03-16 2000-09-21 Merck Frosst Canada & Co. Gamma-ketoacid dipeptides as inhibitors of caspase-3
CN1176941C (zh) 1999-04-09 2004-11-24 西托维亚公司 Caspase抑制剂及其应用
ES2274795T3 (es) 1999-07-19 2007-06-01 Merck Frosst Canada Ltd. Pirazinonas, composiciones que contienen tales compuestos.
EP1163208B1 (en) 1999-08-06 2004-05-12 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
CN1235875C (zh) 1999-08-27 2006-01-11 西托维亚公司 取代的α－羟基酸天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
PE20011267A1 (es) 2000-03-29 2001-12-15 Vertex Pharma Carbamato como inhibidores de caspasa
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
TR200200767T1 (tr) 2000-05-23 2002-09-23 Vertex Pharmaceuticals Incorporated Kaspaz engelleyiciler ve kullanımları
EP1289993B9 (en) 2000-06-07 2008-08-20 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
CA2315468A1 (en) 2000-08-10 2002-02-10 Thermax International Corp. Multi grouting system
WO2002022611A2 (en) 2000-09-13 2002-03-21 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
AU2002232541A1 (en) 2000-11-21 2002-06-03 Vertex Pharmaceuticals Incorporated Imidazole and benzimidazole caspase inhibitors and uses thereof
US20030096737A1 (en) 2001-04-19 2003-05-22 Anita Diu-Hercend Caspase inhibitors and uses thereof
US6875765B2 (en) 2001-05-10 2005-04-05 Warner-Lambert Company Arylsulfonamide ethers, and methods of use thereof
JP4428926B2 (ja) 2001-05-23 2010-03-10 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびそれらの使用
AU2002348533A1 (en) 2001-10-09 2003-05-26 Vertex Pharmaceuticals Incorporated Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof
CA2475653A1 (en) 2002-02-08 2003-09-04 Idun Pharmaceuticals, Inc. (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US7410956B2 (en) 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
WO2004002401A2 (en) 2002-04-05 2004-01-08 Cytovia, Inc. Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents
US7138395B2 (en) 2002-06-10 2006-11-21 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
US7041696B2 (en) 2002-06-17 2006-05-09 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
PE20040728A1 (es) 2002-06-28 2004-10-23 Vertex Pharma Inhibidores de caspasa
TW200500343A (en) 2002-12-20 2005-01-01 Vertex Pharma Caspase inhibitors and uses thereof
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
SI1633189T1 (sl) * 2003-05-19 2017-12-29 Prothena Biosciences Limited Skrajšani fragmenti alfa-sinukleina pri bolezni Lewyjevih telesc
NZ544472A (en) 2003-07-03 2009-04-30 Myriad Genetics Inc Compounds and therapeutical use thereof
WO2005047860A2 (en) * 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US20050202508A1 (en) 2003-11-12 2005-09-15 Pasinetti Guilio M. Biomarker for Parkinson's disease
KR20070032700A (ko) 2004-05-20 2007-03-22 폴드알엑스 파마슈티칼스, 인크. 트랜스티레틴을 안정화하고 트랜스티레틴 미스폴딩을억제하기 위한, ２-((헤테로)아릴)-벤즈옥사졸 화합물 및유도체, 그리고 조성물 및 방법
CA2567080A1 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
EP1802303B1 (en) 2004-09-17 2011-11-02 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting a-synuclein toxicity
WO2006086517A2 (en) 2005-02-08 2006-08-17 The Scripps Research Institute Inhibitors of transthyretin amyloid fibril formation
US20070092889A1 (en) 2005-06-02 2007-04-26 Perlegen Sciences, Inc. Parkinson's disease-related disease compositions and methods
NZ570103A (en) 2006-01-26 2011-11-25 Foldrx Pharmaceuticals Inc Compounds and methods for modulating protein trafficking
EP1993523A4 (en) 2006-02-17 2009-06-10 Joanne Mclaurin COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
EP2074223A4 (en) 2006-09-15 2010-03-10 Foldrx Pharmaceuticals Inc TEST PROCEDURE FOR THE DETECTION OF PROTEINS IN THE NATIVE CONDITION AND FOR THE IDENTIFICATION OF THE STABILITY OF PROTEINS IN THE NATIVE CONDITION MODULATING COMPOUNDS
US8450481B2 (en) 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
EP2300000A1 (en) * 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
US20120276019A1 (en) * 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
WO2010054127A1 (en) 2008-11-05 2010-05-14 Elan Pharmaceuticals, Inc. Methods and agents for stabilizing non-pathological amyloidogenic polypeptides
AU2009328505B2 (en) * 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
US9116157B2 (en) * 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker
US20130289022A1 (en) * 2010-11-05 2013-10-31 Brandeis University Tetrameric alpha-synuclein and use thereof

Also Published As

Publication number Publication date
JP2014503191A (ja) 2014-02-13
JP2013543129A (ja) 2013-11-28
US20140309172A1 (en) 2014-10-16
US20160143985A1 (en) 2016-05-26
WO2012061785A3 (en) 2013-07-04
WO2012061786A1 (en) 2012-05-10
WO2012061785A2 (en) 2012-05-10
US9116157B2 (en) 2015-08-25
EP2635906A4 (en) 2014-04-02
JP6006908B2 (ja) 2016-10-12
US20130316384A1 (en) 2013-11-28
EP2635907A4 (en) 2014-04-16
EP2635906A2 (en) 2013-09-11
EP2635907A1 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
JP5980790B2 (ja) バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン
EP0787146B1 (en) Compounds and methods for inhibiting beta-protein filament formation and neurotoxicity
JP3694303B2 (ja) 可溶性β−アミロイド・ペプチドの検出のための方法及び組成物
US20090123459A1 (en) Compositions and method for the diagnosis, prevention and treatment of alzheimer's disease
EP2039367A1 (en) Prophylactic/therapeutic agent for neurodegenerative disease
JP4242128B2 (ja) 脳アミロイドーシス予防・治療薬のスクリーニング方法
US20040123334A1 (en) Methods of treating neurodegenerative diseases
US20220034913A1 (en) Methods and compostions of detecting and treating neurodegenerative disorders
AU2018287319B2 (en) Modulators of alpha-synuclein
TWI334784B (en) Compositions and methods for suppression of amyloid plaque formation associated with neurodegenerative disorders
KR20180023870A (ko) Arl6ip1의 유전성 강직성 하반신마비의 치료 용도
AU760536B2 (en) Chaperone suppression of ataxin-1 aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
EP3070096A1 (en) A peptide or collection of peptides derived from amyloid precursor protein
US10947311B2 (en) VCAM-1 mediated methods and compositions for treating aging-associated impairments
Falkon Endo/Lysosomal Uptake and Degradation of Protein Aggregates in Tauopathy
Zhang Role of misfolded SOD1 in neurodegenerative diseases
Shan et al. APP ubiquitination by VHL protein is essential for MVB sorting and lysosomal degradation
WO2014207122A1 (en) Tomoregulin in the treatment of neurological diseases
AU2008200489B2 (en) Methods and compositions for the detection of soluble beta-amyloid peptide
Pannaccione et al. Doctorate School in Molecular Medicine Doctorate Program in Neuroscience Coordinator: Prof Lucio Annunziato XXVIII Cycle
EP2678026A1 (en) Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
Shapiro The role of S-100B in CNS development, maintenance and pathology
Fahnestock Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease
Pike Studies on the role of beta-amyloid protein in the neurodegeneration of Alzheimer's disease
Wang et al. iPSC-Induced Neurons with the V337M MAPT Mutation are Selectively Vulnerable to Caspase-Mediated Cleavage of Tau and Apoptotic Cell Death

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141009

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160704

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160727

R150 Certificate of patent or registration of utility model

Ref document number: 5980790

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees